Overview of Financial Performance

The company’s financial performance in the first quarter of 2024 was impacted by the lingering effects of the COVID-19 pandemic, though there are signs of improvement. Revenue and profits were down compared to the same period last year due to slower enrollment in clinical trials caused by the pandemic. However, patient visits have rebounded which is helping enrollment numbers.

The company pursued opportunities presented by the pandemic, such as designing a clinical trial to test one of its compounds for COVID-19 treatment. It also plans to participate in a study on treatments for long COVID symptoms.

The company has taken measures to conserve cash and maintains adequate liquidity. As of March 31, 2024, available cash and cash equivalents totaled $47.1 million. The company believes it has sufficient working capital to fund operations through at least the end of 2025.

Revenue and Profit Trends

The company does not currently generate revenue. The net loss for Q1 2024 was $2.8 million compared to $2.5 million in Q1 2023. The increased loss is primarily attributable to higher research and development costs related to manufacturing expenses for the MN-166 compound.

Net Loss

Quarter	Net Loss
Q1 2024	$2.8 million
Q1 2023	$2.5 million

General and administrative costs decreased due to lower stock option expenses, providing some offset to the increased R&D costs.

Strengths and Weaknesses

Strengths

• Strong cash position with funding for operations through at least end of 2025
• Pursuing opportunities related to COVID-19 treatment
• Continued progress with clinical trials and drug development programs

Weaknesses

• Clinical trial enrollment slowed by pandemic
• No revenue being generated currently
• Increased expenses related to R&D and manufacturing

Future Outlook

The company expects R&D costs to continue increasing through 2024 as clinical trials progress. However, patient visits and enrollment numbers are rebounding.

The company plans to continue monitoring possible impacts from the pandemic and macroeconomic conditions. A resurgence of COVID-19 or other health epidemic could disrupt operations and adversely affect the business.

The company may raise additional capital through equity offerings if needed to finance operations and development programs. Cost control measures have been implemented to conserve cash when possible.

The outlook for the remainder of 2024 is cautious due to the pandemic and economic uncertainty. However, the company is positioned to weather adverse conditions with its strong cash reserves. Progress continues with the clinical pipeline and pursuit of opportunities related to COVID-19.